Revisiting the Outstanding Questions in Cancer Nanomedicine with a Future Outlook

Overview

Journal Nanoscale Adv

Publisher Royal Society of Chemistry

Specialty Biotechnology

Date 2022 Sep 22

PMID 36131837

Authors

M S Sudheesh

K Pavithran

Sabitha M

Affiliations

Soon will be listed here.

Abstract

The field of cancer nanomedicine has been fueled by the expectation of mitigating the inefficiencies and life-threatening side effects of conventional chemotherapy. Nanomedicine proposes to utilize the unique nanoscale properties of nanoparticles to address the most pressing questions in cancer treatment and diagnosis. The approval of nano-based products in the 1990s inspired scientific explorations in this direction. However, despite significant progress in the understanding of nanoscale properties, there are only very few success stories in terms of substantial increase in clinical efficacy and overall patient survival. All existing paradigms such as the concept of enhanced permeability and retention (EPR), the stealth effect and immunocompatibility of nanomedicine have been questioned in recent times. In this review we critically examine impediments posed by biological factors to the clinical success of nanomedicine. We put forth current observations on critical outstanding questions in nanomedicine. We also provide the promising side of cancer nanomedicine as we move forward in nanomedicine research. This would provide a future direction for research in nanomedicine and inspire ongoing investigations.

Citing Articles

Nanotechnology for the theranostic opportunity of breast cancer lung metastasis: recent advancements and future challenges.

Miao L, Kang Y, Zhang X Front Bioeng Biotechnol. 2024; 12:1410017.

PMID: 38882636 PMC: 11176448. DOI: 10.3389/fbioe.2024.1410017.

Intervaginal space injection of photothermal chemotherapy nanoparticles for facilitating tumor targeting and improving outcomes in mice.

Liu Y, Su M, Wang Y, Du Y, Wang Y, Hu N Heliyon. 2024; 10(5):e27408.

PMID: 38468940 PMC: 10926121. DOI: 10.1016/j.heliyon.2024.e27408.

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer.

Zeng W, Luo Y, Gan D, Zhang Y, Deng H, Liu G Front Bioeng Biotechnol. 2023; 11:1271420.

PMID: 38047286 PMC: 10693343. DOI: 10.3389/fbioe.2023.1271420.

Synthetic molecular motor activates drug delivery from polymersomes.

Guinart A, Korpidou M, Doellerer D, Pacella G, Stuart M, Dinu I Proc Natl Acad Sci U S A. 2023; 120(27):e2301279120.

PMID: 37364098 PMC: 10319042. DOI: 10.1073/pnas.2301279120.

Influence of Elasticity of Hydrogel Nanoparticles on Their Tumor Delivery.

Chen X, Zhang S, Li J, Huang X, Ye H, Qiao X Adv Sci (Weinh). 2022; 9(29):e2202644.

PMID: 35981891 PMC: 9561785. DOI: 10.1002/advs.202202644.

References

Sabnani M, Rajan R, Rowland B, Mavinkurve V, Wood L, Gabizon A . Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. Nanomedicine. 2014; 11(2):259-62. DOI: 10.1016/j.nano.2014.08.010. View

Brown E, McKee T, DiTomaso E, Pluen A, Seed B, Boucher Y . Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003; 9(6):796-800. DOI: 10.1038/nm879. View

Gabizon A, Shmeeda H, Barenholz Y . Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42(5):419-36. DOI: 10.2165/00003088-200342050-00002. View

Sykes E, Dai Q, Sarsons C, Chen J, Rocheleau J, Hwang D . Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc Natl Acad Sci U S A. 2016; 113(9):E1142-51. PMC: 4780626. DOI: 10.1073/pnas.1521265113. View

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

Jain P, Pawar R, Pandey R, Madan J, Pawar S, Lakshmi P . In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link?. Biotechnol Adv. 2017; 35(7):889-904. DOI: 10.1016/j.biotechadv.2017.08.003. View

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R . Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013; 8(10):772-81. DOI: 10.1038/nnano.2013.181. View

Shan H, Dou W, Zhang Y, Qi M . Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth. Nanoscale. 2020; 12(43):22268-22280. DOI: 10.1039/d0nr04520a. View

10.

Lynch I, Dawson K, Linse S . Detecting cryptic epitopes created by nanoparticles. Sci STKE. 2006; 2006(327):pe14. DOI: 10.1126/stke.3272006pe14. View

11.

YATES J, WALLACE Jr H, ELLISON R, HOLLAND J . Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973; 57(4):485-8. View

12.

Chang C, Chen C, Chen B, Su Y, Chen Y, Hershfield M . A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nat Commun. 2017; 8(1):522. PMC: 5595925. DOI: 10.1038/s41467-017-00622-4. View

13.

Szebeni J, Simberg D, Gonzalez-Fernandez A, Barenholz Y, Dobrovolskaia M . Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018; 13(12):1100-1108. PMC: 6320688. DOI: 10.1038/s41565-018-0273-1. View

14.

Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S . Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-80. PMC: 1876882. DOI: 10.1016/S0002-9440(10)65006-7. View

15.

Beutier H, Hechler B, Godon O, Wang Y, Gillis C, de Chaisemartin L . Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis. Sci Immunol. 2018; 3(22). DOI: 10.1126/sciimmunol.aan5997. View

16.

Shimizu T, Ishida T, Kiwada H . Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology. 2012; 218(5):725-32. DOI: 10.1016/j.imbio.2012.08.274. View

17.

Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-66. PMC: 1857267. DOI: 10.1172/JCI31422. View

18.

Matsumoto Y, Nichols J, Toh K, Nomoto T, Cabral H, Miura Y . Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat Nanotechnol. 2016; 11(6):533-538. DOI: 10.1038/nnano.2015.342. View

19.

Hu Q, Rijcken C, Bansal R, Hennink W, Storm G, Prakash J . Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials. 2015; 53:370-8. DOI: 10.1016/j.biomaterials.2015.02.085. View

20.

Rampado R, Crotti S, Caliceti P, Pucciarelli S, Agostini M . Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of "Stealthy" Nanomaterials. Front Bioeng Biotechnol. 2020; 8:166. PMC: 7145938. DOI: 10.3389/fbioe.2020.00166. View